Gene therapy trial aims to restore night vision in rare eye disease
NCT ID NCT06388200
First seen Jun 27, 2026 · Last updated Jul 31, 2026 · Updated 1 time
Summary
This study tests a gene therapy called OCU400 for people with retinitis pigmentosa, an inherited eye disease that causes vision loss. The treatment is injected under the retina to help light-sensitive cells work better. The trial enrolled 140 people aged 3 and older and measures if they can navigate a maze in dim light after one year.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RETINITIS PIGMENTOSA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Advanced Research, LLC.
Deerfield Beach, Florida, 33064, United States
-
Associated Retina Consultants
Phoenix, Arizona, 85020, United States
-
Bascom Palmer Eye Institute, University of Miami, Miller School of Medicine
Miami, Florida, 33136, United States
-
Baylor College of Medicine
Houston, Texas, 77030, United States
-
Calgary Retina Consultants
Calgary, Alberta, T2H OC8, Canada
-
Erie Retina Research LLC
Erie, Pennsylvania, 16507, United States
-
Gundersen Health System
La Crosse, Wisconsin, 54601, United States
-
Research Institute of the McGill University Health Centre
Montreal, Quebec, H2W 1L4, Canada
-
Retina Consultants of Texas
Bellaire, Texas, 77401, United States
-
Retina Foundation of the Southwest
Dallas, Texas, 75231, United States
-
Sunnybrook Health Sciences Centre
Toronto, Ontario, M4N 3M5, Canada
-
The University of British Columbia
Vancouver, British Columbia, V5Z 3N9, Canada
-
University of Alberta
Edmonton, Alberta, T6G 3E1, Canada
-
University of Southern Califormia
La Jolla, California, 92093, United States
-
University of Southern California, Roski Eye Insitute
Los Angeles, California, 90033, United States
-
Valley Retina Institute
McAllen, Texas, 78503, United States
-
Vanderbilt Eye Institute
Nashville, Tennessee, 37232, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a single eye injection restore sight in genetic blindness?
- A sharper look at the retina: new imaging technology may spot eye disease earlier
- Stem cell eye transplant aims to halt blindness from rare genetic disease
- Could stem cells restore sight in damaged eyes?
- Gene therapy injection aims to restore sight in rare blindness
- Ground-Level vision test could help retinitis pigmentosa patients walk better